ABM Reagents

<h2 dir="ltr">What Are AAV Control &amp; Reporter Constructs?</h2>
 Establishing reliable experimental controls is critical in AAV research because transduction efficiency varies substantially by serotype, cell type, multiplicity of infection (MOI), and batch-to-batch variation in viral preparation quality. Matched AAV control and reporter constructs provide the reference point for interpreting experimental results.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Promoter-Specific Blank Vectors used for baseline control, utilize neuron-specific hSyn promoters and high-purity plasmids&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Matched Blank Viruses for precise tissue-targeting validation. Available pre-packaged in serotypes 1 through 11
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Bioluminescent Reporter Systems for sensitive measurement of viral delivery.&nbsp; And gene expression featuring luciferase and SV40-luc markers
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Fluorescent Control Constructs carry circ-GFP, GFP, and CBh-gcGFP, for real-time transduction tracking.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Circular RNA Control Plasmids for advanced non-coding RNA research.&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Cloning-Ready Expression Backbones for selected gene insertion and viral packaging workflows using ampicillin-resistant blank vectors
</li>
</ul>
<h2 dir="ltr"> How to Choose AAV Control &amp; Reporter Constructs </h2>
 Serotype and Backbone Matching The control construct should use the same AAV serotype, ITR configuration, and promoter as the experimental construct, ensuring transduction efficiency differences reflect the transgene rather than vector or serotype variation. Fluorescent Reporter Choice GFP and mCherry reporters allow confirmation of transduction by fluorescence microscopy or flow cytometry, with mCherry offering a red-channel option for multiplexed experiments. Luciferase and Dual-Reporter Options Firefly luciferase provides quantitative bioluminescent transduction confirmation; dual reporter systems (e.g., fluorescent + luciferase) allow both visual and quantitative readouts from the same construct. Empty Vector Baseline An empty AAV vector &mdash; same ITRs, serotype, and promoter, no transgene &mdash; establishes the baseline effect of AAV capsid delivery and innate immune activation, independent of the gene of interest. Batch-to-Batch Variation Controls Because AAV preparation quality can vary between batches, including a transduction-efficiency control (e.g., GFP reporter) alongside each new batch of experimental AAV helps confirm comparable functional titer. 
<h2 dir="ltr"> Specifications Context</h2>
 AAV transduction can activate innate immune sensing pathways and, at high vector doses, induce cellular stress responses independently of the transgene. A matched empty vector or reporter control sharing the same serotype and promoter as the experimental construct helps distinguish vector-related effects from genuine transgene-specific phenotypes. Because AAV infectivity can vary between preparations, reporter-based transduction assessments are commonly used to verify functional performance before experimental studies. For in vivo applications, pilot reporter studies can help confirm tissue targeting and delivery efficiency before larger cohorts are committed. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team </a>at MBP today to get high-quality control/reporter vectors for your lab.

Control/Reporter

Lentiviral Vector Amplification Protocol

AAV Infection Guideline

AAV Packaging Protocol

Selection-Drug Killing Curve

Lentivector Packaging Protocol

Lentivirus Infection Protocol

AAV-hSyn-Blank-CBh-GFP Control Vector

AAV-hSyn-Blank-CBh-GFP Control Vector Blank1012 (ABM) — 1.0 µg. Blank hSynapsin (neuron-specific) AAV control with CBh-gcGFP reporter. For negative control in hSyn-driven AAV neuronal expression experiments. GFP confirms transduction. Package into desired AAV serotype before use. Store −20 °C. RUO.

Unit Quantity

Vector Map

List of Markers

Shipping Condition

AAV-hSyn-Blank-SV40-Luc Control Vector

AAV-hSyn-Blank-SV40-Luc Control Vector (Blank1013) by Applied Biological Materials is a 1.0 µg insert-empty AAV plasmid with neuron-specific hSyn promoter and SV40-Luciferase reporter, for use as a negative control in neuronal AAV gene expression studies.

<h2 dir="ltr">What Are AAV Purification &amp; Packaging Kits?</h2>
 Producing high-titer, high-purity recombinant AAV is a prerequisite for reproducible in vitro and in vivo gene delivery experiments. Impure AAV preparations containing cell debris, empty capsids, and residual transfection reagents reduce functional titer, increase immune activation, and compromise experimental reproducibility. Consistent AAV production requires efficient packaging and purification. Select the kit designed for your vector workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
AAV Packaging Mix(1-6) for serotype-specific and efficient gene delivery and AAV production&nbsp;
</li>
<li dir="ltr" aria-level="1">
AAV Serotype Blast&trade; Kit for greater viral yield and enhanced AAV production workflows
</li>
<li dir="ltr" aria-level="1">
AAViralEntry&trade; Transduction Enhancer for improved uptake of AAV and better delivery in mammalian cells
</li>
<li dir="ltr" aria-level="1">
AAV Serotype Blast&trade; Kit for reliable viral vector constructs and AAV production
</li>
</ul>
<h2 dir="ltr"> How to Choose AAV Purification &amp; Packaging Kits</h2>
 Helper-Free Packaging Components Helper-free triple-transfection requires the transgene plasmid (gene of interest flanked by AAV2 ITRs), the rep/cap plasmid (supplying Rep replication proteins and the serotype-specific capsid), and a helper plasmid supplying adenoviral helper functions &mdash; confirm all three components are available for your chosen serotype. Purification Method Iodixanol gradient purification separates full and empty capsids by density without ultracentrifugation in some protocols, while precipitation-filtration kits offer a simpler benchtop alternative for labs without gradient centrifugation capability. Empty vs. Full Capsid Ratio Empty AAV capsids (lacking packaged genome) contribute to particle count without functional activity and can increase immune response in vivo &mdash; purification methods that enrich for full capsids improve both potency and safety profile. Serotype-Specific Rep/Cap Plasmids Each AAV serotype requires its corresponding rep/cap plasmid; confirm the packaging kit includes (or is compatible with) the rep/cap plasmid for your target serotype. Scale of Production Kit formats differ for small-scale research production versus larger-scale preparations intended for multiple in vivo cohorts &mdash; match kit scale to your experimental throughput needs. 
<h2 dir="ltr"> Specifications Context</h2>
 Helper-free triple transfection eliminates the need for co-infection with a replication-competent helper adenovirus, improving safety and simplifying production for standard BSL-2 laboratories. Iodixanol gradient and precipitation-filtration purification approaches are designed to produce research-grade rAAV without requiring ultra-centrifuge access, broadening accessibility for labs setting up AAV production for the first time. As with all recombinant AAV work, production requires institutional biosafety committee (IBC) approval at BSL-2 containment in most jurisdictions. Labs producing AAV for the first time should also plan for functional titering after purification by qPCR for genome copies and by transduction assay for infectious titer, since these two measures can differ substantially, and the functional titer is the more relevant figure for planning experimental MOIs. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team</a> at MBP to confirm packaging system compatibility and serotype availability for your application.

Purification & Packaging Kits

Purfication & Packaging Kits

DataSheet

AAViralEntry™ Transduction Enhancer (100X)

G516 by Applied Biological Materials is a 100X concentrated rAAV transduction enhancer formulated as a positively charged fatty acid polymer that promotes rAAV–cell membrane interaction across multiple serotypes. Validated for recombinant AAV only — not suitable for lentivirus or adenovirus. 1.0 ml; dilute to 1X in media. Store at 4°C (6 months) or &minus;20°C (1 year).

Storage Condition

<h2 dir="ltr">What Are AAV miRNA Negative Controls?</h2>
 MicroRNA (miRNA) research requires matched controls that enter the same delivery pathway as experimental constructs. AAV-delivered miRNA controls are particularly important for experiments in primary cells and in vivo models, where conventional transfection-based controls would not reflect the same delivery-related effects. The right miRNA control ensures accurate interpretation of miRNA-mediated effects. Choose a control matched to your expression and analysis workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Specific AAV miRNA Controls as blank control viruses used for precise tissue tropism matching.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
GFP-Tagged miRNA Control Viruses use fluorescent protein markers for successful transduction verification.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
pAAV-mir-GFP-hGH-amp Plasmids used for reliable cloning and feature ampicillin resistance and hGH polyadenylation&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
miRNA-OFF Blank Control Vectors used to validate miRNA inhibition specificity&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Ready-to-Use Control Virions used in comparative gene silencing for immediate use.
</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV miRNA Negative Control</h2>
 Delivery Pathway Matching When miRNA is delivered via AAV, the control must also be AAV-delivered &mdash; to account for capsid-mediated innate immune activation and viral DNA sensing effects that alter cellular transcription independently of the miRNA sequence itself. Mimic vs. Inhibitor Format Non-targeting miRNA mimic controls (gain-of-function studies) and non-targeting miRNA inhibitor controls (loss-of-function studies) require different control designs matching the experimental approach. Serotype and Promoter Matching The AAV miRNA control should share the same serotype and promoter as the experimental AAV-delivered miRNA construct to ensure comparable tissue tropism and expression timing. In Vivo vs. In Vitro Application AAV-delivered miRNA controls are particularly relevant for in vivo gain-of-function or loss-of-function studies, where AAV's broad tissue tropism and long-term expression make it the delivery method of choice. Validation of Off-Target Effects As with other RNAi-pathway controls, non-targeting designs should be validated to have minimal homology to known miRNA targets in the relevant species. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
When miRNA is delivered via AAV, the control should also be AAV-delivered to account for vector-related effects such as capsid interactions and cellular responses to the viral genome. This distinguishes AAV-based controls from transfection-derived controls, which do not capture AAV-specific delivery effects. Matching the serotype and promoter configuration of the control vector to the experimental construct helps ensure that observed phenotypes are attributable to the miRNA rather than differences in vector design. Researchers planning in vivo studies should obtain control and experimental AAV preparations with comparable production and quality metrics where possible, as differences in titer or purity can introduce unwanted variability. Including both an AAV-delivered control and, where appropriate, an untreated cohort can further aid interpretation of miRNA-specific effects. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team</a> at MBP Inc. to discuss the most suitable AAV miRNA control constructs for your study and request a quote tailored to your research requirements.

miRNA Control

AAV-mir-GFP Control Virus (Serotype 1)

AAV-mir-GFP-Blank Control Virus (Serotype 1) (Am00101) by Applied Biological Materials is a packaged AAV1 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 1-matched, insert-free negative control in AAV1-delivered miRNA experiments. Also available as plasmid (Am00101a). Shipped on dry ice; store at –80°C.

Description

Vector Map (Am00101)

Vector Map (Am00101a)

AAV-mir-GFP-Blank Control Virus (Serotype 1)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 1)

AAV-mir-GFP-Blank Control Virus (Serotype 10)

AAV-mir-GFP-Blank Control Virus (Serotype 10) (Am00110) by Applied Biological Materials is a packaged AAV10 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 10-matched, insert-free negative control in AAV10-delivered miRNA experiments. Also available as plasmid (Am00110a). Shipped on dry ice; store at –80°C.

Titer

Vector Map (Am00110)

Vector Map (Am00110a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 10)

AAV-mir-GFP-Blank Control Virus (Serotype 3)

AAV-mir-GFP-Blank Control Virus (Serotype 3) (Am00103) by Applied Biological Materials is a packaged AAV3 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 3-matched, insert-free negative control in AAV3-delivered miRNA experiments. Also available as plasmid (Am00103a). Shipped on dry ice; store at –80°C.

Vector Map (Am00103)

Vector Map (Am00103a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 3)

AAV-mir-GFP-Blank Control Virus (Serotype 4)

AAV-mir-GFP-Blank Control Virus (Serotype 4) (Am00104) by Applied Biological Materials is a packaged AAV4 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 4-matched, insert-free negative control in AAV4-delivered miRNA overexpression experiments. Also available as plasmid (Am00104a). Shipped on dry ice; store at –80°C.

Vector Map (Am00104)

Vector Map (Am00104a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 4)

AAV-mir-GFP-Blank Control Virus (Serotype 5)

AAV-mir-GFP-Blank Control Virus (Serotype 5) (Am00105) by Applied Biological Materials is a packaged AAV5 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 5-matched, insert-free negative control in AAV5-delivered miRNA overexpression experiments. Also available as plasmid (Am00105a). Shipped on dry ice; store at –80°C.

Vector Map (Am00105)

Vector Map (Am00105a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 5)

AAV-mir-GFP-Blank Control Virus (Serotype 6)

AAV-mir-GFP-Blank Control Virus (Serotype 6) (Am00106) by Applied Biological Materials is a packaged AAV6 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 6-matched, insert-free negative control in AAV6-delivered miRNA experiments. Also available as plasmid (Am00106a). Shipped on dry ice; store at –80°C.

Vector Map (Am00106)

Vector Map (Am00106a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 6)

AAV-mir-GFP-Blank Control Virus (Serotype 7)

AAV-mir-GFP-Blank Control Virus (Serotype 7) (Am00107) by Applied Biological Materials is a packaged AAV7 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 7-matched, insert-free negative control in AAV7-delivered miRNA experiments. Also available as plasmid (Am00107a). Shipped on dry ice; store at –80°C.

Vector Map (Am00107)

Vector Map (Am00107a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 7)

AAV-mir-GFP-Blank Control Virus (Serotype 8)

AAV-mir-GFP-Blank Control Virus (Serotype 8) (Am00108) by Applied Biological Materials is a packaged AAV8 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 8-matched, insert-free negative control in AAV8-delivered miRNA experiments. Also available as plasmid (Am00108a). Shipped on dry ice; store at –80°C.

Vector Map (Am00108)

Vector Map (Am00108a)

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 8)

AAV-mir-GFP-Blank Control Virus (Serotype 9)

AAV-mir-GFP-Blank Control Virus (Serotype 9) (Am00109) by Applied Biological Materials is a packaged AAV9 miRNA blank control virus with GFP reporter and hGH polyA signal, supplied as 5 × 100 µl for use as a serotype 9-matched, insert-free negative control in AAV9-delivered miRNA experiments. Also available as plasmid (Am00109a). Shipped on dry ice; store at –80°C.